Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Common Equity (2016 - 2017)

Tenax Therapeutics' Common Equity history spans 7 years, with the latest figure at $10.2 million for Q3 2017.

  • For Q3 2017, Common Equity fell 78.23% year-over-year to $10.2 million; the TTM value through Sep 2017 reached $10.2 million, down 78.23%, while the annual FY2016 figure was $17.1 million, N/A changed from the prior year.
  • Common Equity for Q3 2017 was $10.2 million at Tenax Therapeutics, down from $11.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $82.9 million in Q2 2014 and bottomed at -$1.6 million in Q1 2013.
  • The 5-year median for Common Equity is $31.9 million (2016), against an average of $36.2 million.
  • The largest annual shift saw Common Equity fell 15.0% in 2015 before it plummeted 78.23% in 2017.
  • A 5-year view of Common Equity shows it stood at -$1.6 million in 2013, then surged by 5276.61% to $82.9 million in 2014, then fell by 27.07% to $60.4 million in 2015, then tumbled by 71.63% to $17.1 million in 2016, then tumbled by 40.7% to $10.2 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Common Equity are $10.2 million (Q3 2017), $11.3 million (Q2 2017), and $14.1 million (Q1 2017).